Introduction 2021 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Reports
recommends that patients with clinically significant symptoms and exacerbations of chronic …

Background This study aims to compare the effects of single inhaler triple therapy comprised
of inhaled corticosteroids (ICSs), long-acting β2-agonists (LABAs), and long-acting …

Introduction Treatment of chronic obstructive pulmonary disease (COPD) is evolving
specially with triple inhaler therapy. Objectives To perform a meta‐analysis to ascertain the …

Background Guidelines recommend that treatment with a long-acting β 2 agonist (LABA), a
long-acting muscarinic antagonist (LAMA), and inhaled corticosteroids (ICS), ie triple …

We systematically reviewed the current knowledge on fixed-dose triple therapies for the
treatment of chronic obstructive pulmonary disease (COPD), with a specific focus on its …

Randomized trials of triple therapy including an inhaled corticosteroid (ICS) for chronic
obstructive pulmonary disease (COPD) reported remarkable benefits on mortality compared …

A systematic review and Bayesian network meta-analysis is necessary to evaluate the
efficacy and safety of triple therapy with different doses of inhaled corticosteroids (ICS) in …

Guidelines are mainly based on evidence of well-designed randomized controlled trials
(RCTs), but there are limitations to the transferability of conclusions of RCTs to usual care …

Triple inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting β2-
agonist (LABA) therapy is recommended for symptomatic patients with chronic obstructive …

Treatment guidelines for patients with symptomatic advanced COPD at high risk of
exacerbations (GOLD Group D) recommend triple therapy using long-acting muscarinic …